177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
Status:
RECRUITING
Trial end date:
2030-11-01
Target enrollment:
Participant gender:
Summary
Single-center, non-commercial phase 2 clinical trial to evaluate 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment using locoregional teleradiotherapy and hormone therapy
Phase:
PHASE2
Details
Lead Sponsor:
Maria Sklodowska-Curie National Research Institute of Oncology